Anjaneya Bapat

Dr. Anjaneya Bapat

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
SAS Agrawal
S Agrawal
ABAnjaneya Bapat
Anjaneya Bapat
JAJ Amos
J Amos
EHE Howes
E Howes
TAT Ashfield
T Ashfield
Life-saving immunosuppressive treatments including intensive chemotherapy and bone marrow transplantation expose patients to a considerable risk of death from infection globally. With evolving AMR and transmission, this could spell disaster for patients across the world and society at large. Antimicrobial stewardship (AMS) and prompt appropriate management of potentially fatal, emergent infections are essential. It is now apparent that antibacterial prophylaxis in patients with haematological cancer may not provide survival benefit while simultaneously increasing risks for AMR carriage. With evolving AMR and increasing immunosuppressed populations across the world, we must institute robust AMS practices. Significant resources are used to combat the impact of AMR on immunosuppressed patients. For lower-middle income countries (LMICs) these resources may not be available and as such the impact caused by AMR is greater. By considering the patient journey holistically we consider risk of infection presented to patients temporally and geographically. A short-term and easy to implement approach of multi-disciplinary team (MDT)-style advance care planning for infection is advocated. Antimicrobials, when used appropriately, enable healthcare procedures to occur and exist. Indeed, the very future of clinical medicine will rely on this yet to be realized value of enablement. Proactive effort and change must occur across all sectors with holism; hence our impetus for convening a joint industry and clinical working group. With at-risk immunosuppressed groups being a sentinel for change, awareness and implementation of patient-centric actions for infection are essential and our recommendations serve as an urgent call to action.

19 December 2022 in Journal of Medical Microbiology
Verified
Journal Article
Open access
ABAnjaneya Bapat
Anjaneya Bapat
OLOlivia Lucey
Olivia Lucey
MEMartyn Eckersley
Martyn Eckersley
HCHolly Ciesielczuk
Holly Ciesielczuk
SRSherika Ranasinghe
Sherika Ranasinghe
JLJonathan Lambourne
Jonathan Lambourne
Introduction. Aggregatibacter are Gram-negative, facultatively anaerobic rods or coccobacilli that are infrequently encountered as pathogens causing infection. Hypothesis/Gap Statement. The range of invasive infection that Aggregatibacter cause is poorly described. The pathogenicity of species such as Aggregatibacter segnis is debated. Aim. To identify invasive infection due to Aggregatibacter species in a large healthcare organization and to characterize clinical syndromes, co-morbidities and risk factors. Methodology. All microbiological samples positive for Aggregatibacter species were identified by conventional culture or 16S rRNA PCR between October 2017 and March 2021. Electronic records for all patients with positive samples were reviewed and the infection syndrome classified for patients with invasive disease. Results. Twenty-seven patients with invasive infection were identified, with a statistically significant difference in species-specific patterns of invasive infection (P=0.02) and a statistically significant association with residence in the 30 % most deprived households in the UK by postcode (P<0.01). The three most common co-morbidities were periodontitis or recent dental work (29.6%), cardiovascular disease (25.9%) and diabetes (18.5 %). Conclusion. We describe a novel association of Aggregatibacter segnis with skin and soft tissue infection. The propensity of the Aggregatibacter species to cause invasive infection at different body sites and be associated with deprivation is reported. Aggregatibacter actinomycetemcomitans bacteraemia was associated with infective endocarditis, and Aggregatibacter aphrophilus was implicated in severe appendicitis and noted to cause brain abscess. Areas warranting future research include exploring the risk-factors required for invasive infection and those that may determine the species-specific differences in patterns of invasive disease.

21 October 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
VAVictoria B Allen
Victoria B Allen
ARAhmed Raslan
Ahmed Raslan
AMAnn Maria Muuli
Ann Maria Muuli
NANoor Yehya Alkhafaji
Noor Yehya Alkhafaji
KBKatie Bechman
Katie Bechman
KAKeyoumars Ashkan
Keyoumars Ashkan
Background: Brain abscess is a serious infection with substantial morbidity and mortality. Current data on the etiology, management, and outcomes are limited. This study describes the epidemiology of brain abscess in a large patient cohort. Methods: This is a retrospective, observational study of brain abscess at a tertiary referral center. Patients were selected using hospital coding. Demographic, clinical, neurosurgical, and microbiological data were analyzed. Results: We identified 174 patients with brain abscess admitted between 2012 and 2023 (32 pediatric, 142 adults, 66.7% male). Subdural empyema and parenchymal abscess were the most common abscess types in the pediatric and adult cohorts, respectively. A microbiological diagnosis was made in 74.1% of cases. Staphylococcus aureus was the most common cause of postsurgical brain abscess, causing 27.8% of these cases. Streptococcus anginosus caused 42.8% of community-acquired brain abscesses. Microbiological samples were sent for 16S rRNA gene polymerase chain reaction (PCR) testing in 33 cases (19.0%). A new microbiological diagnosis was made in 14 of these 33 cases (42.4%). In-hospital mortality was 13.4%. Increasing age and poor admission Glasgow Coma Score were significantly associated with mortality. A trend toward decreasing mortality was seen with S. anginosus. Conclusions: Our data reinforce the importance of early diagnosis and multidisciplinary management, particularly in older patients. Molecular diagnostics, including 16S rRNA gene PCR, may play an increasing role in guiding treatment in the future.

8 January 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
HWHannah Ward
Hannah Ward
AAAlireza Abdolrasouli
Alireza Abdolrasouli
COCurtis Offiah
Curtis Offiah
SASamir Agrawal
Samir Agrawal
EHEfthymios Hadjimichael
Efthymios Hadjimichael
ABAnjaneya Bapat
Anjaneya Bapat
: We report a case of co-infection with Aspergillus fumigatus causing invasive sino-orbital aspergillosis and Trichophyton interdigitale tinea corporis in a returned traveler from flooded Sylhet region, Bangladesh. Anthropogenic climate change may lead to increased extreme weather–associated fungal infections. Travel to a flooded area should be considered a risk factor for fungal infection.

6 April 2022 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
ABAnjaneya Bapat
Anjaneya Bapat
BNBeatrice Nickel
Beatrice Nickel
TBTimothy J. P. Bray
Timothy J. P. Bray
MAMaaz Abbasi
Maaz Abbasi
NSNeil R. H. Stone
Neil R. H. Stone
Gnathostomiasis, caused by infection with nematode parasites in the genus Gnathostoma, is endemic in tropical and temperate zones, and is classically associated with East and Southeast Asia and, more recently, Latin America and Africa. We report a case of gnathostomiasis acquired in Costa Rica, which has not previously been considered an endemic country. The patient had eosinophilia with migratory myalgia, and the diagnosis was made after serological testing. Full resolution of symptoms and eosinophilia followed treatment with ivermectin and albendazole. The diagnosis can be challenging to make because of variability in presentation, lack of access to diagnostics, and emerging knowledge of endemic areas. Increased awareness of this disease among clinicians is vital for faster diagnosis and better outcomes in afflicted patients.

10 March 2025 in eJHaem
Verified
Journal Article
Open access
SASamir Agrawal
Samir Agrawal
ABAnjaneya Bapat
Anjaneya Bapat
CEChris Eades
Chris Eades
SGShreyans Gandhi
Shreyans Gandhi
Objective: To examine the incidence of invasive fungal disease (IFD) in patients receiving targeted agents for acute myeloid leukaemia (AML).Methods: Literature for this systematic review was identified through a PubMed search in April 2024, using AML, IFD and targeted therapy terms. The following filters were applied: published in the last 10 years and published in English.Results: The PubMed search yielded 54 results, of which 16 were deemed relevant for inclusion. Four additional references were identified through manual searches. The majority of publications focused on the incidence of IFD during treatment with targeted agents; the remainder focused on the efficacy of targeted treatments and reported IFD as an adverse event. Most publications were retrospective analyses. Prophylaxis use and agents differed across studies. In several studies, IFD incidence was above the 8% threshold identified for anti‐mould prophylaxis. Aspergillus was the most commonly reported pathogen, and most IFD cases occurred in the lungs.Conclusions: IFD is relatively common among patients with AML receiving targeted therapies, despite the use of prophylaxis. Prospective studies with detailed IFD reporting, together with large epidemiological studies, are required to better understand the risk factors for, and incidence and nature of IFD in this patient population.